Abstract 1408P
Background
Non-small cell lung cancer (NSCLC) can harbor different KRAS mutations. Although targeted therapy is available for KRAS G12C-mutant NSCLC, immune checkpoint inhibitors (ICIs) are still the first line treatment (tx) for these patients (pts). Here we aimed to assess the outcomes on ICIs for KRAS G12C compared to KRAS non-G12C-mutant pts.
Methods
This is an observational, retrospective, multicenter study in pts with KRAS-mutant NSCLC treated with ICIs (monotherapy or combination) between January 2017 and January 2023. Targeted sequencing was performed in most cases. Clinicopathological and molecular data were collected. We evaluated pts characteristics, tx response and survival outcomes from the beginning of ICIs in KRAS G12C vs non-G12C tumors.
Results
A total of 169 pts were included. NGS was performed in 105 pts, STK11 and TP53 were the most frequent co-mutated genes present in 4.4%/15% G12C/non-G12C (p=0.110) and 20%/35% G12C/non-G12C (p=0.143), respectively. There were no differences in median progression free survival (PFS) between G12C/non-G12C (8.8 vs 7.1 months(m) respectively p=0.727). In the multivariate analysis, PD-L1 negative tumors and ECOG ≥1 remained independently associated with worse PFS (p=0.010 and p= 0.002 respectively). Regarding overall survival (OS), harboring a G12C mutation was associated with a better OS compared with non-G12C tumors (mOS 16.2m vs 10.4m p=0.033), conversely PD-L1 negative tumors and basal ECOG of ≥1 was associated with worse OS (p= 0.002 and p<0.001 respectively).
Table: 1408P
Patient’s characteristics
N (%) | G12C (n=75) | Non-G12c (n=94) | p-value |
Median age | 62.9 | 63.8 | 0.471 |
Sex | 0.220 | ||
Male | 45 (60) | 66 (70.2) | |
Female | 30 (40) | 28 (29.7) | |
Tobacco | 0.203 | ||
Former | 34 (45.4) | 53 (56,4) | |
Current | 41 (54.6) | 41 (43.6) | |
Stage | 0.630 | ||
I-III | 17 (21.7) | 22 (23,4) | |
IV | 58 (78.3) | 72 (76.6) | |
M1 CNS | 14 (18.6) | 24 (25.5) | 0.381 |
M1 liver | 14 (18.6) | 20 (21.3) | 0.820 |
ICIs treatment line | 0.604 | ||
1 | 57 (76) | 75 (80) | |
≥2 | 18 (24) | 19 (20) | |
PD-L1 | 0.397 | ||
Negative (0%) | 17 (22.7) | 30 (32) | |
Positive (≥0%) | 58 (77.3) | 64 (68) | |
ECOG | 0.887 | ||
0 | 31 (41.4) | 41 (43.6) | |
≥1 | 44 (58.6) | 53 (56.4) |
Conclusions
Our work shows that patients with KRAS non-G12C tumors are more frequently PD-L1 negative and harbor a higher proportion of STK11 co-mutations conditioning a worse OS on immunotherapy treatment. Innovative therapeutic strategies need to be investigated for these patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
L. Masfarre Pinto: Other, Personal, Other, Travel Support: Kyowa Kirin. N. Castro Unanua: Financial Interests, Personal, Invited Speaker: Pierre Fabre; Financial Interests, Personal, Ownership Interest, Travel, congress registration: Merck, Roche; Financial Interests, Personal, Ownership Interest, Grant support: Expert Degree in Immuno-Oncology: Bristol Myers Squibb; Financial Interests, Personal, Ownership Interest, Travel: Pfizer. P. Rocha: Non-Financial Interests, Personal, Other, Travel Support: AstraZeneca. B. Bellosillo Paricio: Other, Personal, Other, Grant: Thermo Fisher, Roche Diagnostics, Roche Farma, AstraZeneca; Other, Personal, Other, Consultant: Amgen, AstraZeneca, Janssen, Novartis; Other, Personal, Speaker’s Bureau: Janssen, Merck-Serono, Novartis, Qiagen, Thermo Fisher, Pfizer, Bristol Myers Squibb. H. Arasanz: Other, Personal, Advisory Board: AstraZeneca; Other, Personal and Institutional, Other, Clinical Trial Coordination: Ferrer Farma; Other, Personal, Other, accommodation/travel expenses: Takeda, MSD, Angelini Farma. E. Arriola: Financial Interests, Personal, Advisory Board: Roche, Boehringer Ingelheim, Lilly; Financial Interests, Personal, Invited Speaker: Takeda, MSD, AstraZeneca, BMS, Thermo Fisher Scientific, Guardant Health, Pfizer; Financial Interests, Personal, Other, Co-founder: Trialing Health; Financial Interests, Institutional, Research Grant: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
1368P - LUMINATE 102: A real-world study on biomarker testing rates among patients with non-small cell lung cancer (NSCLC) across lines of therapy
Presenter: Charu Aggarwal
Session: Poster session 20
1369P - BrigAlec study: Focus on alectinib efficacy after brigatinib exposure in BrigALK2 study (GFPC 02-2019)
Presenter: Renaud Descourt
Session: Poster session 20
1370P - Efficacy and safety of ensartinib in ALK-positive non-small cell lung cancer patients with brain metastases: A multicenter, open-label, single-arm, phase II study
Presenter: Jianhua Chang
Session: Poster session 20
1371P - First-line alectinib vs. brigatinib in advanced metastatic NSCLC with ALK rearrangement: Real-world data
Presenter: Young Kyung Jeon
Session: Poster session 20
1372P - Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial
Presenter: Ben Solomon
Session: Poster session 20
1373P - Efficacy and safety of taletrectinib in patients (Pts) with ROS1+ non-small cell lung cancer (NSCLC): Interim analysis of global TRUST-II study
Presenter: Maurice Pérol
Session: Poster session 20
1374P - Survival and therapy analysis of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients
Presenter: Moritz Glaser
Session: Poster session 20
1375P - Beamion Lung 1, an ongoing phase Ia/Ib trial of the HER2 TKI, BI 1810631 in patients (pts) with advanced solid tumors with HER2 aberrations: Latest data
Presenter: Frans Opdam
Session: Poster session 20
1377P - Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity
Presenter: Xiuning Le
Session: Poster session 20
1378P - Efficacy and safety of tunlametinib (HL-085) combined with vemurafenib in patients with advanced BRAF V600-mutated solid tumors: A multicenter, phase I study
Presenter: Yuan-Kai Shi
Session: Poster session 20